Rising Prevalence of Hypercalcemia to Drive Asia Pacific Market Growth

Triveni Triveni
Published on Apr 19, 2023

The Hypercalcemia Market on a global level is anticipated to exhibit a stable compound annual growth rate (CAGR) in terms of revenue over the forecast period. The market's revenue growth for hypercalcemia treatment has been driven by the escalating risk of hypercalcemia as a result of increasing occurrences of cancer (including lung, breast, and blood cancer) and hyperparathyroidism. The utilization of advanced technology has enabled greater spending on drug research and development, which has led to the development of highly innovative and novel drugs that are expected to drive market revenue growth in the forecast period. Hypercalcemia is a medical condition characterized by higher than normal levels of calcium in the bloodstream. Calcium is a critical mineral that is essential for maintaining hormone balance, supporting bone strength and growth, and facilitating proper functioning of the brain, muscles, and nervous system. Elevated blood calcium levels can be caused by certain treatments and medical conditions. If left untreated for an extended period, high calcium levels in the blood can lead to complications such as bone loss and fractures, kidney stones, kidney failure, hypertension, and slowed heart rate, among others.

A significant patient population affected by hypercalcemia, coupled with a high prevalence of cancer and hyperparathyroidism, is expected to create favorable conditions for market expansion. The market's growth is further expected to be driven by increased research and development efforts focused on developing novel therapies to address significant clinical needs that remain unmet. Furthermore, increased government support, public and private initiatives aimed at raising awareness about the importance of regular medical checkups, improved healthcare infrastructure, and increased healthcare spending are expected to create a wide range of opportunities. The market for hypercalcemia is predicted to grow due to the increasing use of monoclonal antibodies such as denosumab, a human RANKL antibody that reduces osteoclast activity and bone loss. Denosumab has been found to be more effective than zoledronic acid in delaying or preventing hypercalcemia of malignancy in patients with advanced cancer, including multiple myeloma, breast cancer, and other solid tumors. It also functions in cases of hypercalcemia where bisphosphonates are ineffective.

Request a sample Report of Hypercalcemia Market @

Major companies in Hypercalcemia Market:

  • Amgen Inc.
  • Cipla, Inc.
  • Novartis AG
  • Aetna Inc.
  • Actiza Pharmaceutical Private Limited
  • Bristol-Myers Squibb Company
  • Sun Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Reddy’s Laboratories Ltd.
  • Bayer AG
  • Kyowa Hakko Kirin Co Ltd.

Request latest Report Insights of  Hypercalcemia Market @

Driving Factors in Hypercalcemia Market:

  1. Increasing prevalence of hypercalcemia due to rising cancer occurrences (including lung, breast, and blood cancer) and hyperparathyroidism.
  2. Development of innovative and novel medicines due to increased spending on drug discovery and research operations through enhanced technology.
  3. Greater government assistance, private and public initiatives to raise awareness about the importance of routine medical examinations, enhanced healthcare infrastructure, and an increase in healthcare spending.
  4. Large patient pools of hypercalcemia coupled with high cancer prevalence and hyperparathyroidism, creating favorable conditions for market expansion.
  5. Development of branded medications by significant regional players, well-established healthcare facilities, a strong product pipeline of key players, and increased prescription of novel drugs.
  6. Improved regional reimbursement policies and an increase in research and development initiatives to produce efficient treatment alternatives.
  7. Growing use of monoclonal antibodies, such as the human RANKL antibody denosumab, that reduce osteoclast activity and bone loss.

Restraints in Hypercalcemia Market:

  1. Limited awareness about the condition and its treatment options among patients and healthcare professionals.
  2. High cost of treatment, which may limit access to care for some patients.
  3. Side effects associated with current treatments for hypercalcemia, such as bisphosphonates and calcimimetics.
  4. Limited availability of effective treatments for hypercalcemia in some regions.
  5. Stringent regulatory requirements for approval of new treatments, which may delay their availability to patients.
  6. Risk of drug resistance and lack of response to current treatments in some patients.
  7. Uncertainty in healthcare policies and reimbursement frameworks, which may impact market growth and investment decisions.

Request a Report Customization of Hypercalcemia Market @

Notable Innovations in Hypercalcemia Market:

  1. Monoclonal antibodies: Monoclonal antibodies, such as denosumab, have been developed to treat hypercalcemia by reducing osteoclast activity and bone loss. Denosumab has been found to be more effective than bisphosphonates at delaying or preventing hypercalcemia of malignancy in patients with advanced cancer, including multiple myeloma, breast cancer, and other solid tumors.
  2. Calcimimetics: Calcimimetics, such as cinacalcet, have been developed to treat hypercalcemia associated with hyperparathyroidism. These drugs work by increasing the sensitivity of calcium-sensing receptors in the parathyroid gland, leading to a decrease in parathyroid hormone (PTH) secretion and serum calcium levels.
  3. Radiopharmaceuticals: Radiopharmaceuticals, such as radium-223, have been developed to treat bone metastases associated with advanced prostate cancer. These drugs work by selectively targeting cancer cells in the bone, delivering high doses of radiation to the tumor while minimizing damage to healthy tissue.
  4. Gene therapy: Gene therapy is being explored as a potential treatment option for hypercalcemia. Researchers have developed a gene therapy approach using an adenovirus vector to deliver the human parathyroid hormone (hPTH) gene to the parathyroid gland, resulting in decreased PTH secretion and serum calcium levels.
  5. Nanoparticle-based therapies: Nanoparticle-based therapies, such as nanoliposomal alendronate, are being developed to target hyperactive bone resorption and treat hypercalcemia associated with bone metastases. These therapies work by delivering bisphosphonates or other agents directly to the bone, minimizing systemic side effects and improving treatment efficacy.

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, TouchPoints, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provide our clients with the ability to secure an edge over their respective competitors.

Contact Us:

John W
Head of Business Development
Reports And Data | Web:
Direct Line: +1-212-710-1370
LinkedIn | Twitter | Blogs